Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.
Chronic relapsing experimental allergic encephalomyelitis (CR.EAE) was induced by immunizing Lewis rats with total guinea-pig spinal cord (GPSC) tissue emulsified in enriched complete Freund's adjuvant (CFA). The proliferative responses of draining inguinal and popliteal lymph node cells to GP.MBP, purified protein derivative (PPD) and concanavalin A (ConA) appeared significantly modulated according to the clinical state of the animals. Responses appeared significantly decreased in both lymphoid compartments during the recovery periods compared with that during relapses. Therapeutic treatment of CR.EAE with cyclosporin and different lysolecithin derivatives, such as ET-18-OCH3, SRI 62-843 and MLS 266-337, starting at the spontaneous remission of the first disease bout, could suppress the manifestation of further relapses. Whereas cyclosporin only delayed the onset of the disease relapse until discontinuation of treatment, all lysolecithins showed a curative effect in most animals. Plasma corticosterone levels measured at different time points in placebo, cyclosporin and MLS 266-377-treated rats showed a strong correlation with the clinical state of the animals. High corticosterone levels were detected during stages of acute paralysis, whereas a decrease to normal levels was noted during each recovery phase.
Kovarik
J
J
Sandoz Pharma Ltd, Basel, Switzerland.
Chabannes
D
D
Borel
J F
JF
D000818:Animals; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003208:Concanavalin A / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006168:Guinea Pigs; D008198:Lymph Nodes / Q000473:pathology; D008213:Lymphocyte Activation; D008244:Lysophosphatidylcholines / Q000627:therapeutic use*; D009103:Multiple Sclerosis; D004676:Myelin Basic Protein / Q000494:pharmacology; D010742:Phospholipid Ethers / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D014373:Tuberculin / Q000494:pharmacology
D005663:Furans; D008244:Lysophosphatidylcholines; D004676:Myelin Basic Protein; D010742:Phospholipid Ethers; D014373:Tuberculin; D003208:Concanavalin A; C055462:SRI 62-834; C026659:edelfosine; D003907:Dexamethasone; D016572:Cyclosporine; D003345:Corticosterone